MeiPai
Develops ceramic 3D printing systems and materials for industrial and medical applications.
- CEO / Founder
- Li Hongshu (李宏书)
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- Undisclosed
- Latest Round
- Angel
- Key Investors
- Shanghai Science and Technology Investment
Technology & Products
Key Products
MP-100 Ceramic 3D Printer; MP-200 Industrial Series; Alumina (Al2O3) slurry; Zirconia (ZrO2) slurry; Hydroxyapatite (HA) bio-ceramic materials; Custom ceramic printing services
Technological Advantage
Claimed: Superior surface finish (Ra < 2μm) and mechanical strength comparable to injection molding. Verified: Multiple Chinese patents for slurry stability and light curing optimization. Defensible: Proprietary material recipes and software compensation algorithms for shrinkage control.
Differentiation
Value Proposition
Enables production of complex technical ceramic components with >99% density, eliminating $10k+ tooling costs and reducing lead times from 8 weeks to 48 hours for aerospace and medical prototypes.
How They Differentiate
Provides comparable 25μm resolution to Lithoz CeraFab systems but at approximately 40-50% lower total cost of ownership for Chinese domestic customers through localized supply chains and technical support.
Market & Competition
Target Customers
Industrial and medical organizations requiring ceramic additive manufacturing solutions.
Industry Verticals
Industrial; Medical
Competitors
Lithoz; 3DCeram; TenYue
Growth & Milestones
Major Milestones
2015: Founded in Shanghai; 2017: Secured Angel funding from Shanghai Science and Technology Investment; 2018: Commercial launch of MP-100; 2020: Expansion into bio-ceramic medical implants
Notable Customers
Shanghai Ninth People's Hospital; CASIC (China Aerospace Science and Industry Corporation); Various Chinese university research labs